iRadimed (IRMD) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed iRadimed (IRMD) over the past year, gaining 52.3% versus a gain of 16.0%. Over five years, IRMD leads with a +138.5% price change compared with -90.4% for PACB. iRadimed is the larger company by market cap ($1.12 billion vs $724.2 million), about 1.5 times the size.
iRadimed pays a dividend yielding 0.88%, while Pacific Biosciences of California does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRMD | PACB |
|---|---|---|
| Share price | $87.45 | $2.33 |
| Market cap | $1.12B | $724.24M |
| 1-day change | +1.83% | +1.30% |
| YTD return | -10.10% | +24.60% |
| 1-year return | +15.95% | +52.29% |
| 5-year return | +138.48% | -90.45% |
| P/E ratio (TTM) | 48.85 | — |
| Forward P/E | 35.65 | — |
| EPS (TTM) | $1.79 | $-0.43 |
| Dividend yield | 0.88% | 0.00% |
| Annual dividend | $0.77 | $0.00 |
| Revenue (latest FY) | $83.81M | — |
| Revenue growth (YoY) | +14.43% | — |
| Net income (latest FY) | $22.48M | — |
| Gross margin | 76.75% | — |
| Operating margin | 31.20% | — |
| Net margin | 26.82% | — |
| 52-week high | $107.90 | $3.44 |
| 52-week low | $71.34 | $1.07 |
| Distance from 52-week high | -18.95% | -32.27% |
| Analyst consensus | none | buy |
| Avg. price target upside | +34.93% | +3.00% |
| Average volume | 125.83K | 10.39M |
| Shares outstanding | 12.79M | 310.83M |
| Employees | 166 | 485 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PACB has outperformed IRMD by 36.3 percentage points over the past year.
About iRadimed
IRMD stock →IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Healthcare · Medical Devices · 166 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Healthcare · Medical Devices · 485 employees
IRMD vs PACB FAQ
Which is bigger, iRadimed or Pacific Biosciences of California?
iRadimed (IRMD) is larger, with a market capitalization of $1.12B compared with $724.24M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, IRMD or PACB?
PACB returned +52.29% over the past 12 months, compared with +15.95% for IRMD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, iRadimed or Pacific Biosciences of California?
iRadimed pays a dividend yielding 0.88%, while Pacific Biosciences of California does not currently pay a regular dividend.
Are iRadimed and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.